A large genome-wide association study (GWAS) of schizophrenia identified 108 independent genetic loci associated with the disorder, with 83 of these loci previously unreported. The study included 36,989 cases and 113,075 controls, and the findings were enriched in genes expressed in the brain, supporting biological plausibility. Associations were also enriched in genes related to immunity, suggesting a potential link between the immune system and schizophrenia. The study highlights genes involved in glutamatergic neurotransmission and dopamine signaling, which are relevant to schizophrenia treatment. The results suggest that common genetic variants contribute to schizophrenia risk, and that these variants may influence gene expression rather than protein structure. The study also found overlap between schizophrenia-associated genes and those with de novo mutations in other disorders, indicating shared pathophysiological mechanisms. Polygenic risk scores were shown to predict case-control status, although with limited sensitivity and specificity. The study underscores the importance of genetic research in understanding schizophrenia and improving treatment options. The findings provide new insights into the biological mechanisms underlying schizophrenia and highlight the potential for further research into the role of genetic variation in the disorder.A large genome-wide association study (GWAS) of schizophrenia identified 108 independent genetic loci associated with the disorder, with 83 of these loci previously unreported. The study included 36,989 cases and 113,075 controls, and the findings were enriched in genes expressed in the brain, supporting biological plausibility. Associations were also enriched in genes related to immunity, suggesting a potential link between the immune system and schizophrenia. The study highlights genes involved in glutamatergic neurotransmission and dopamine signaling, which are relevant to schizophrenia treatment. The results suggest that common genetic variants contribute to schizophrenia risk, and that these variants may influence gene expression rather than protein structure. The study also found overlap between schizophrenia-associated genes and those with de novo mutations in other disorders, indicating shared pathophysiological mechanisms. Polygenic risk scores were shown to predict case-control status, although with limited sensitivity and specificity. The study underscores the importance of genetic research in understanding schizophrenia and improving treatment options. The findings provide new insights into the biological mechanisms underlying schizophrenia and highlight the potential for further research into the role of genetic variation in the disorder.